CN103108548A - 使用环酰胺衍生物治疗σ受体介导的病症的方法 - Google Patents

使用环酰胺衍生物治疗σ受体介导的病症的方法 Download PDF

Info

Publication number
CN103108548A
CN103108548A CN2011800450188A CN201180045018A CN103108548A CN 103108548 A CN103108548 A CN 103108548A CN 2011800450188 A CN2011800450188 A CN 2011800450188A CN 201180045018 A CN201180045018 A CN 201180045018A CN 103108548 A CN103108548 A CN 103108548A
Authority
CN
China
Prior art keywords
alkyl
compound
mean
treatment
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800450188A
Other languages
English (en)
Chinese (zh)
Inventor
R.H.卢思林格
L.佩勒格里尼
A.N.卡拉贝拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Cyrenaic Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyrenaic Pharmaceuticals Inc filed Critical Cyrenaic Pharmaceuticals Inc
Priority to CN201611063838.0A priority Critical patent/CN107007603A/zh
Publication of CN103108548A publication Critical patent/CN103108548A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Plant Pathology (AREA)
  • Psychology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2011800450188A 2010-07-20 2011-07-20 使用环酰胺衍生物治疗σ受体介导的病症的方法 Pending CN103108548A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611063838.0A CN107007603A (zh) 2010-07-20 2011-07-20 使用环酰胺衍生物治疗σ受体介导的病症的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36608010P 2010-07-20 2010-07-20
US61/366080 2010-07-20
PCT/US2011/044698 WO2012012543A1 (en) 2010-07-20 2011-07-20 Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201611063838.0A Division CN107007603A (zh) 2010-07-20 2011-07-20 使用环酰胺衍生物治疗σ受体介导的病症的方法

Publications (1)

Publication Number Publication Date
CN103108548A true CN103108548A (zh) 2013-05-15

Family

ID=45497167

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800450188A Pending CN103108548A (zh) 2010-07-20 2011-07-20 使用环酰胺衍生物治疗σ受体介导的病症的方法
CN201611063838.0A Pending CN107007603A (zh) 2010-07-20 2011-07-20 使用环酰胺衍生物治疗σ受体介导的病症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201611063838.0A Pending CN107007603A (zh) 2010-07-20 2011-07-20 使用环酰胺衍生物治疗σ受体介导的病症的方法

Country Status (15)

Country Link
US (4) US20130274290A1 (enExample)
EP (2) EP4070794A3 (enExample)
JP (3) JP2013531073A (enExample)
KR (1) KR101867634B1 (enExample)
CN (2) CN103108548A (enExample)
BR (1) BR112013001302A2 (enExample)
CA (2) CA3154027A1 (enExample)
DK (1) DK2595485T3 (enExample)
ES (1) ES2914120T3 (enExample)
HU (1) HUE058736T2 (enExample)
PL (1) PL2595485T3 (enExample)
PT (1) PT2595485T (enExample)
RU (2) RU2746871C2 (enExample)
TW (1) TWI520949B (enExample)
WO (1) WO2012012543A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107567444A (zh) * 2014-12-02 2018-01-09 田边三菱制药株式会社 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
EP3463356A1 (en) * 2016-05-25 2019-04-10 Minerva Neurosciences, Inc. Compositions and methods for treating negative symptoms in non-schizophrenic patients
EP3641732A1 (en) * 2017-06-21 2020-04-29 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
BR112021002654A2 (pt) * 2018-08-21 2021-05-04 Minerva Neurosciences, Inc. uso de roluperidona para tratar sintomas e distúrbios negativos, aumentar a neuroplasticidade e promover neuroproteção
IL298323B2 (en) 2020-05-20 2023-10-01 Univ Illinois A method for treating lysosomal storage disease using histatin peptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006297A1 (en) * 1989-10-27 1991-05-16 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
JPH07506107A (ja) * 1992-04-23 1995-07-06 メレルダウファーマスーティカルズ　インコーポレイテッド セロトニン５ｈｔ↓２拮抗剤としての４‐イミドメチル‐１‐［２’フェニル‐２’オキソエチル‐］ピペリジン類，それらの製法及び治療用途
CN1426405A (zh) * 2000-02-29 2003-06-25 三菱制药株式会社 新型环状酰胺衍生物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903857A1 (en) * 1989-10-27 1991-05-08 Du Pont Merck Pharma (N-Phthalimidoalkyl)Piperidines
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006297A1 (en) * 1989-10-27 1991-05-16 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
JPH07506107A (ja) * 1992-04-23 1995-07-06 メレルダウファーマスーティカルズ　インコーポレイテッド セロトニン５ｈｔ↓２拮抗剤としての４‐イミドメチル‐１‐［２’フェニル‐２’オキソエチル‐］ピペリジン類，それらの製法及び治療用途
CN1426405A (zh) * 2000-02-29 2003-06-25 三菱制药株式会社 新型环状酰胺衍生物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107567444A (zh) * 2014-12-02 2018-01-09 田边三菱制药株式会社 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物

Also Published As

Publication number Publication date
RU2017105262A (ru) 2019-01-18
KR20130129906A (ko) 2013-11-29
CA2805904A1 (en) 2012-01-26
JP2013531073A (ja) 2013-08-01
KR101867634B1 (ko) 2018-06-15
HUE058736T2 (hu) 2022-09-28
US20130274290A1 (en) 2013-10-17
BR112013001302A2 (pt) 2017-07-04
EP2595485A4 (en) 2014-04-23
US20250228838A1 (en) 2025-07-17
RU2746871C2 (ru) 2021-04-21
JP6419294B2 (ja) 2018-11-07
CA3154027A1 (en) 2012-01-26
EP2595485B1 (en) 2022-03-16
EP4070794A2 (en) 2022-10-12
JP2016199578A (ja) 2016-12-01
RU2613201C2 (ru) 2017-03-15
DK2595485T3 (da) 2022-05-30
RU2017105262A3 (enExample) 2019-01-18
TWI520949B (zh) 2016-02-11
CA2805904C (en) 2022-06-21
CN107007603A (zh) 2017-08-04
ES2914120T3 (es) 2022-06-07
TW201211022A (en) 2012-03-16
WO2012012543A1 (en) 2012-01-26
PL2595485T3 (pl) 2022-06-20
RU2013107378A (ru) 2014-08-27
US20160354357A1 (en) 2016-12-08
JP2018065829A (ja) 2018-04-26
EP2595485A1 (en) 2013-05-29
PT2595485T (pt) 2022-05-30
EP4070794A3 (en) 2023-01-18
US20210106573A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
JP6419294B2 (ja) シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法
US11958852B2 (en) Compounds and methods
CN115154470B (zh) 使用食欲素-2受体拮抗剂治疗抑郁症的方法
JP7514534B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
US20190167676A1 (en) Methods for improving resistance to skeletal muscle fatigue
JP2019510039A (ja) 新規組成物および方法
WO2014078377A1 (en) Methods and compositions for treating schizophrenia
MX2007011436A (es) Ligando del receptor nicotinico neuronal 7 y composiciones antipsicoticas.
KR20070038503A (ko) 신규 헤테로시클릭 카르복시산 아미드 유도체
US20100009983A1 (en) 5 ht receptor mediated neurogenesis
CN103220910A (zh) 使用环酰胺衍生物治疗精神分裂症的方法
RU2840025C2 (ru) Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств
EA011636B1 (ru) Производные амида кинуреновой кислоты как антагонисты nr2b подтипа рецептора nmda
WO2008118326A1 (en) Muscarinic agonists and methods of use thereof
JP2024156953A (ja) 認知症患者における行動・心理症状を治療するための方法
AU2010257456A1 (en) 5 HT receptor mediated neurogensis
CA2726300A1 (en) 5 ht receptor mediated neurogenesis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
CB02 Change of applicant information

Address after: New jersey, USA

Applicant after: MINERVA NEUROSCIENCES, Inc.

Address before: New jersey, USA

Applicant before: CYRENAIC PHARMACEUTICALS, Inc.

COR Change of bibliographic data
TA01 Transfer of patent application right

Effective date of registration: 20161228

Address after: Osaka City, Osaka of Japan

Applicant after: MITSUBISHI TANABE PHARMA Corp.

Address before: New jersey, USA

Applicant before: MINERVA NEUROSCIENCES, Inc.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130515